Abstract:The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). It can be used to conduct both single-agent and drug-combination trials. The BOIN design is motivated by the top priority and concern of clinicians, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. The most important advantage of the BOIN design is that it is easy to implement in practice and has superior operating characteristics. The BOIN design is algorithm-based and thus can be implemented in a way similar to the traditional “3+3” design. The performance of the BOIN design is comparable to that of the continual reassessment method (CRM, one of the best performing model-based phase I trial designs) in terms of selecting the MTD, but has a lower risk of assigning patients to subtherapeutic or overly toxic doses (i.e., better patient ethics). The idea behind the BOIN design is straightforward. The conduct of phase I trials can be viewed as a sequence of decision-making steps of dose assignment for patients who are sequentially enrolled into a trial. At each moment of decision making, based on the observed data, we take one of three actions: escalate, deescalate or retain the current dose. Under the standard assumption that efficacy monotonically increases with toxicity (for cytotoxic agents), an ideal trial design would escalate the dose when the current dose is below the MTD in order to avoid treating a patient at a subtherapeutic dose level; deescalate the dose when the current dose is above the MTD in order to avoid exposing a patient to an overly toxic dose; and retain the same dose level when the current dose is equal (or close) to the MTD. However, such an ideal design is not available in practice because we do not know whether the current dose is actually below, above or equal (or close) to the MTD, and need to

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Bayesian phase I/II adaptively randomized oncology trials with combined drugs

Comparative review of novel model-assisted designs for phase I clinical trials.

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations

A comparison of model-free phase I dose escalation designs for dual-agent combination therapies

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

A Nonparametric Bayesian Design for Drug Combination Cancer Trials

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.